Genome variation and personalized cancer medicine

Journal of Internal Medicine

Volumn 274, Issue 5, 2013, Pages 440-450

  Hudson, T J ^a  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Biomarkers; Cancer; Genomic medicine; Personalized medicine

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HISTONE DEMETHYLASE; K RAS PROTEIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; SMAD7 PROTEIN; TRANSCRIPTION FACTOR GATA 2;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER CELL; CANCER GENETICS; CANCER MORTALITY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; DNA REPAIR; DRUG RESPONSE; ENVIRONMENTAL FACTOR; ERECTILE DYSFUNCTION; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOMIC VARIATION; GENOTYPE; HEALTH CARE QUALITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; LIVER CANCER; MEDULLOBLASTOMA; METASTASIS; MISMATCH REPAIR; MUTATION RATE; NONHUMAN; OCCULT BLOOD; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMATIC MUTATION; URINE INCONTINENCE;

BIOMARKERS; CANCER; GENOMIC MEDICINE; PERSONALIZED MEDICINE;

CEREBELLAR NEOPLASMS; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MEDULLOBLASTOMA; NEOPLASM METASTASIS; NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; SURVIVORS;

EID: 84885750897     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12097     Document Type: Review

References (57)

1. Wong KM, Hudson TJ, McPherson JD. Unraveling the genetics of cancer: genome sequencing and beyond. Annu Rev Genomics Hum Genet 2011; 12: 407-30.
2. International Cancer Genome Consortium. International network of cancer genome projects. Nature 2010; 464: 993-8.
3. International Cancer Genome Consortium web site, http://icgc.org/.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
5. Mandel JS, Church TR, Bond JH et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-7.
6. Lynch HT, Lynch JF, Attard TA. Diagnosis and management of hereditary colorectal cancer syndromes: Lynch syndrome as a model. CMAJ 2009; 181: 273-80.
7. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
8. Kraft P, Hunter DJ. Genetic risk prediction-are we there yet? N Engl J Med 2009; 360: 1701-3.
9. Zanke BW, Greenwood CM, Rangrej J et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 2007; 39: 989-94.
10. Tomlinson IP, Webb E, Carvajal-Carmona L et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 2008; 40: 623-30.
11. Dunlop MG, Dobbins SE, Farrington SM et al. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 2012; 44: 770-6.
12. Cui R, Okada Y, Jang SG et al. Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. Gut 2011; 60: 799-805.
13. Kinnersley B, Migliorini G, Broderick P et al. The TERT variant rs2736100 is associated with colorectal cancer risk. Br J Cancer 2012; 107: 1001-8.
14. Jia WH, Zhang B, Matsuo K et al. Genome-wide association analyses in east Asians identify new susceptibility loci for colorectal cancer. Nat Genet 2012; 45: 191-6.
15. Peters U, Jiao S, Schumacher FR et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. Gastroenterology 2012; 144: 799-807.
16. Chung CC, Chanock SJ. Current status of genome-wide association studies in cancer. Hum Genet 2011; 130: 59-78.
17. Pittman AM, Naranjo S, Webb E et al. The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. Genome Res 2009; 19: 987-93.
18. Pittman AM, Naranjo S, Jalava SE et al. Allelic variation at the 8q23.3 colorectal cancer risk locus functions as a cis-acting regulator of EIF3H. PLoS Genet 2010; 6; pii: e1001126.
19. Dunlop MG, Tenesa A, Farrington SM et al. Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42 103 individuals. Gut 2012; 62: 871-81.
20. Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol 2013; 10: 38-48.
21. Chou R, Croswell JM, Dana T et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155: 762-71.
22. Greene KL, Albertsen PC, Babaian RJ et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2013; 189: S2-11.
23. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24: 1967-2000.
24. Barbieri CE, Baca SC, Lawrence MS et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-9.
25. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43.
26. Canadian Prostate Cancer Genome Network web site. http://icgc.org/icgc/cgp/70/392/70542.
27. Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 2010; 7: 725-32.
28. Review of mortality results in randomised trials in early breast cancer. Lancet 1984; 2: 1205.
29. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
30. Glas AM, Floore A, Delahaye LJ et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006; 7: 278.
31. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
32. Bartlett J, Canney P, Campbell A et al. Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. Clin Oncol (R Coll Radiol) 2012; 25: 109-16.
33. Wu G, Feng X, Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol 2010; 11: R53.
34. Wu G, Stein L. A network module-based method for identifying cancer prognostic signatures. Genome Biol 2012; 13: R112. [Epub ahead of print]
35. Michalski CW, Weitz J, Büchler MW. Surgery insight: surgical management of pancreatic cancer. Nat Clin Pract Oncol 2007; 4: 526-35.
36. Biankin AV, Waddell N, Kassahn KS et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491: 399-405.
37. Armstrong MD, Von Hoff D, Barber B et al. An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development. J Cancer 2011; 2: 142-52.
38. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011; 10: 3-8.
39. Jones S, Hruban RH, Kamiyama M et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217.
40. Ding L, Ley TJ, Larson DE et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-10.
41. Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell 2012; 148: 409-20.
42. MacConaill LE, Campbell CD, Kehoe SM et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009; 4: e7887.
43. Wagle N, Berger MF, Davis MJ et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2: 82-93.
44. Tran B, Brown AM, Bedard PL et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer 2012; 132: 1547-55.
45. Siegel R, DeSantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-41.
46. Mabbott DJ, Spiegler BJ, Greenberg ML, Rutka JT, Hyder DJ, Bouffet E. Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J Clin Oncol 2005; 23: 2256-63.
47. Northcott PA, Korshunov A, Witt H et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29: 1408-14.
48. Northcott PA, Dubuc AM, Pfister S, Taylor MD. Molecular subgroups of medulloblastoma. Expert Rev Neurother 2012; 12: 871-84.
49. Northcott PA, Shih DJ, Peacock J et al. Subgroup-specific structural variation across 1, 000 medulloblastoma genomes. Nature 2012; 488: 49-56.
50. Jones DT, Jäger N, Kool M et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488: 100-5.
51. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488: 106-10.
52. Raffel C, Jenkins RB, Frederick L et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997; 57: 842-5.
53. Pietsch T, Waha A, Koch A et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997; 57: 2085-8.
54. Wolter M, Reifenberger J, Sommer C, Ruzicka T, Reifenberger G. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997; 57: 2581-5.
55. Rudin CM, Hann CL, Laterra J et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361: 1173-8.
56. Buonamici S, Williams J, Morrissey M et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010; 2: 51ra70.
57. Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM, Rajasekaran SA. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 2011; 11: 144.